Clinical trial
A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of Ralinepag, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension
NCT02279160 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of Ralinepag, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension
- Lead sponsor
- United Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2014
- Completion date
- June 30, 2017
- Enrollment
- 61 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.